Merck to Highlight Data at ESMO 2022 with Potential for Tran

Not intended for US- or Canada-based media Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unresected

Related Keywords

Canada , China , Japan , United States , Eli Lilly , European Society Of Medical Oncology , European Commission , Drug Administration , Pfizer , Head Of Development Unit , Serono , European Society , Medical Oncology , Annual Meeting , Victoria Zazulina , Development Unit , Apoptosis Protein , Solid Tumors , Strategic Sequencing , Quimper Auditorium , Optimize Treatment Outcomes , Advanced Urothelial Carcinoma , Urval Auditorium , Medical Education , Treatment Decisions , Molecular Testing , New Targeted Treatment Options , Oral Session , Neck Cancer , First In Human Phasei Study , Advanced Solid Tumors , Paper Session , Product Characteristics , Clin Oncol , Merck , Highlight , Data , Osmo , 022 , Potential , Ransformative , Impact , Dancer , Patients ,